Polycystic ovary syndrome, combined oral contraceptives and the risk of dysglycemia

Kumarendran, Balachandran; O'reilly, Michael; Subramanian, Anuradhaa; Sumilo, Dana; Toulis, Konstantinos; Gokhale, Krishna; Wijeyaratne, Chandrika N. ; Coomarasamy, Arri; Tahrani, Abd; Azoulay, Laurent; Arlt, Wiebke; Nirantharakumar, Krishnarajah

DOI:
10.2337/dc21-0437

Document Version
Peer reviewed version

Citation for published version (Harvard):
Kumarendran, B, O'reilly, M, Subramanian, A, Sumilo, D, Toulis, K, Gokhale, K, Wijeyaratne, CN, Coomarasamy, A, Tahrani, A, Azoulay, L, Arlt, W & Nirantharakumar, K 2021, 'Polycystic ovary syndrome, combined oral contraceptives and the risk of dysglycemia: a population-based cohort study with a nested pharmaco-epidemiological case-control study', *Diabetes Care*, vol. 44, no. 12, dc210437, pp. 2758-2766. https://doi.org/10.2337/dc21-0437

A. Risk of type 2 diabetes and dysglycaemia within BMI subgroups



B. COCP exposure and risk of dysglycaemia



Normal/Underweight: <23.5 kg/m² for patients of South Asian ethnicity & <25 kg/m² for patients of all other ethnic groups
Overweight: 23.5-27.5 kg/m² for patients of South Asian ethnicity & 25-30 kg/m² for patients of all other ethnic groups
Obese = ≥27.5 kg/m² for patients of South Asian ethnicity & ≥30 kg/m² for patients of all other ethnic groups